CL2020003168A1 - Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis - Google Patents

Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis

Info

Publication number
CL2020003168A1
CL2020003168A1 CL2020003168A CL2020003168A CL2020003168A1 CL 2020003168 A1 CL2020003168 A1 CL 2020003168A1 CL 2020003168 A CL2020003168 A CL 2020003168A CL 2020003168 A CL2020003168 A CL 2020003168A CL 2020003168 A1 CL2020003168 A1 CL 2020003168A1
Authority
CL
Chile
Prior art keywords
mucositis
prevent
host disease
versus
methods
Prior art date
Application number
CL2020003168A
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of CL2020003168A1 publication Critical patent/CL2020003168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención describe el uso de una proteína CD24 para prevenir o tratar la enfermedad de injerto contra huésped y la mucositis
CL2020003168A 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis CL2020003168A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739719P 2018-10-01 2018-10-01
US201862739742P 2018-10-01 2018-10-01

Publications (1)

Publication Number Publication Date
CL2020003168A1 true CL2020003168A1 (es) 2021-06-11

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020003169A CL2020003169A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia
CL2020003168A CL2020003168A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020003169A CL2020003169A1 (es) 2018-06-04 2020-12-04 Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia

Country Status (15)

Country Link
US (2) US20210228680A1 (es)
EP (2) EP3802583A4 (es)
JP (2) JP2021527066A (es)
KR (2) KR20210021317A (es)
CN (2) CN112752766A (es)
AU (2) AU2019282044A1 (es)
BR (2) BR112020024683A2 (es)
CA (2) CA3102372A1 (es)
CL (2) CL2020003169A1 (es)
IL (2) IL279205A (es)
MA (2) MA52811A (es)
MX (2) MX2020013103A (es)
SG (2) SG11202011964SA (es)
TW (2) TW202012015A (es)
WO (2) WO2019236472A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52811A (fr) * 2018-06-04 2022-03-16 Oncoimmune Inc Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA
AU2023258034A1 (en) * 2022-04-20 2024-11-07 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO2009063461A1 (en) 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
CN102250828B (zh) * 2010-11-10 2014-11-05 北京大学 Cd24及cd24抗体的新用途
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US20190119353A1 (en) * 2014-11-06 2019-04-25 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
EP3411062B1 (en) * 2016-02-02 2020-11-25 Oncoimmune Inc. Use of cd24 proteins for treating leptin-deficient conditions
MA52811A (fr) * 2018-06-04 2022-03-16 Oncoimmune Inc Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
US20230157955A1 (en) * 2020-01-08 2023-05-25 Puretech Lyt, Inc. Vesicle compositions for oral delivery

Also Published As

Publication number Publication date
CN112752766A (zh) 2021-05-04
EP3801773A4 (en) 2022-03-16
AU2019282044A1 (en) 2021-01-07
BR112020024659A2 (pt) 2021-03-09
SG11202011963UA (en) 2020-12-30
MA52811A (fr) 2022-03-16
KR20210018294A (ko) 2021-02-17
US11911441B2 (en) 2024-02-27
EP3802583A1 (en) 2021-04-14
KR20210021317A (ko) 2021-02-25
CA3102374A1 (en) 2019-12-12
US20210228680A1 (en) 2021-07-29
BR112020024683A2 (pt) 2021-03-09
WO2019236474A1 (en) 2019-12-12
CA3102372A1 (en) 2019-12-12
JP2021527056A (ja) 2021-10-11
SG11202011964SA (en) 2020-12-30
MA52810A (fr) 2021-04-14
TW202012015A (zh) 2020-04-01
CL2020003169A1 (es) 2021-06-11
CN112512640A (zh) 2021-03-16
IL279204A (en) 2021-01-31
WO2019236472A1 (en) 2019-12-12
JP2021527066A (ja) 2021-10-11
MX2020013100A (es) 2021-02-17
MX2020013103A (es) 2021-05-12
IL279205A (en) 2021-01-31
EP3801773A1 (en) 2021-04-14
EP3802583A4 (en) 2022-03-16
AU2019282530A1 (en) 2021-01-07
TW202015753A (zh) 2020-05-01
US20210268061A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CL2018002359A1 (es) Métodos para usar agonistas de fxr
CU20200042A7 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2020003168A1 (es) Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
UY38352A (es) Inhibidores de integrina alfavbeta6
CL2020000329A1 (es) Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda.
MX392976B (es) Composiciones que comprenden cepas bacterianas.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.